Mycosis Fungoides

• 

  Subject Areas on Research

  • A Case of Multiple Hemorrhagic Friable Nodules. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. 
  • Acquisition of CD30 and CD15 accompanied with simultaneous loss of all pan-T-cell antigens in a case of histological transformation of mycosis fungoides with involvement of regional lymph node: an immunophenotypic alteration resembling classical Hodgkin lymphoma. 
  • Bullous pemphigoid. Occurrence in a patient with mycosis fungoides receiving PUVA and topical nitrogen mustard therapy. 
  • CNS mycosis fungoides: CT and MR findings. 
  • Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. 
  • Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. 
  • Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. 
  • Composite lymphoma of mycosis fungoides and cutaneous small B-cell lymphoma in a 73-year-old male patient. 
  • Defining early mycosis fungoides. 
  • Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. 
  • Differential Response of Mycosis Fungoides Cells to Vorinostat. 
  • Differentiation of human T lymphocytes: II. Phenotypic difference in skin and blood malignant T-cells in cutaneous T-cell lymphoma. 
  • Eccrine gland infiltration by mycosis fungoides. 
  • Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. 
  • Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma. 
  • Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). 
  • Follicular mucinosis as a presenting sign of acute myeloblastic leukemia. 
  • Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. 
  • Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Leukonychia related to vorinostat. 
  • Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. 
  • Meningeal mycosis fungoides: clinical and cellular characteristics. 
  • Meningeal mycosis fungoides: cytologic and ultrastructural aspects. 
  • Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience. 
  • Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides. 
  • Mycosis fungoides. 
  • NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. 
  • Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. 
  • Phenotypic characterization of skin-infiltrating T cells in cutaneous T-cell lymphoma: comparison with benign cutaneous T-cell infiltrates. 
  • Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. 
  • Radiation Therapy for Cutaneous T-Cell Lymphomas. 
  • Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. 
  • Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). 
  • Second malignancies in cutaneous T cell lymphoma. 
  • Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. 
  • Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). 
  • TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). 
  • The United States Cutaneous Lymphoma Consortium (USCLC). 
  • The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. 
  • Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. 
  • United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. 
  • Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.